Adamas Pharmaceuticals (Adamas Pharmaceuticals) Accounts Receivable : $10.05 Mil (As of Sep. 2021)

View and export this data going back to 2014. Start your Free Trial

What is Adamas Pharmaceuticals Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Adamas Pharmaceuticals's accounts receivables for the quarter that ended in Sep. 2021 was $10.05 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Adamas Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2021 was 35.40.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Adamas Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Sep. 2021 was $-1.55.

Adamas Pharmaceuticals Accounts Receivable Historical Data

The historical data trend for Adamas Pharmaceuticals's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adamas Pharmaceuticals Accounts Receivable Chart

Adamas Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Accounts Receivable

Get a 7-Day Free Trial

0.79

0.37

5.51

5.77

8.04

Adamas Pharmaceuticals Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Accounts Receivable	Get a 7-Day Free Trial															7.65	8.04	12.42	10.10	10.05

Adamas Pharmaceuticals Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Adamas Pharmaceuticals Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Adamas Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2021 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	10.046	/	25.896	*	91
=	35.40

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Adamas Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Adamas Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2021 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(83.098	+	0.75 * 10.046	+	0.5 * 8.68	-	165.583
-	0	-	0)	/	45.6906
=	-1.55

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Adamas Pharmaceuticals Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Adamas Pharmaceuticals's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Adamas Pharmaceuticals (Adamas Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adamas Pharmaceuticals Inc (NAS:ADMS) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Powell Street, Suite 1000, Emeryville, CA, USA, 94608

Website

http://www.adamaspharma.com

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.

Executives

Vijay Shreedhar	officer: Chief Commercial Officer	C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL STREET, SUITE 1000 EMERYVILLE CA 94608
Christopher B Prentiss	officer: Chief Financial Officer	1900 POWELL STREET SUITE 750 EMERYVILLE CA 94608
Anna Richo	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David L Mahoney	director	SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Mardi Dier	director	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
William W. Ericson	director, 10 percent owner	777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
John A Macphee	director	C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608
Ivan M Lieberburg	director	11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Michael Bigham	director	890 WINTER STREET, WALTHAM MA 02451
Martha J Demski	director	7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Neil F. Mcfarlane	officer: Chief Executive Officer	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Alfred G Merriweather	officer: Chief Financial Officer
Jennifer J Rhodes	officer: CBO, GC & Compliance Officer	C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Gregory T Went	director, officer: Chief Executive Officer	C/O ADAMAS PHARMACEUTICALS, INC. 2200 POWELL ST, STE 220 EMERYVILLE CA 94608
Rajiv Patni	officer: Chief Medical Officer	C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301